Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
ZTS.MX
STRONG BUYZoetis Inc. · Healthcare · United States · $32.1B · Avg Vol: $5K/d
82
StockRankGet insider-trade alerts
Q
77
V
77
M
21
P/E (TTM)
12.4x
ROE
67.7%
D/E
2.9x
Dividend %
2.7%
COMPANY DESCRIPTION
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.1B | 8.5B | 9.3B | 9.5B | 5.4% | 9.5B | 9.8B | 10.2B | 3.6% |
| EPS | 4.51 | 5.08 | 5.47 | 6.03 | 10.2% | 6.11 | — | — | — |
| Shares | 463.8M | 458.4M | 448.5M | 424.9M | -8.4% | 419.2M | — | — | — |
| Debt | 8.1B | 6.8B | 6.7B | 9.2B | 4.5% | 9.3B | — | — | — |
| Equity | 4.4B | 5.0B | 4.8B | 3.3B | -8.9% | — | — | — | — |
| Op CF | 1.9B | 2.4B | 3.0B | 2.9B | 14.9% | 2.8B | — | — | — |
| Inv CF | -883.0M | -777.0M | -315.0M | -748.0M | — | — | — | — | — |
| Fin CF | -904.0M | -3.1B | -2.7B | -1.9B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-2.2%
SMA 50SMA 200
Close
$75.43
RSI (14)
39.5
52W High
$169.01
From 52W High
0.4%
SCORE BREAKDOWN
Quality
77
ROIC
27.1%95.5
ROE
67.7%98.0
GP/Assets
44.3%83.0
Op. Margin
36.6%95.8
FCF/Assets
14.8%93.1
Piotroski
667.3
Int. Cover
16.1x67.0
D/E Ratio
2.86x3.8
Current Ratio
3.15x56.2
Value
77
P/E (TTM)
12.4x82.7
EV/EBITDA
7.9x80.3
P/FCF
14.0x74.2
P/B
0.5x94.8
P/S
3.3x53.7
Div Yield
2.7%62.2
Momentum
21
52W High %
45%17.2
RS 6M
-46%21.1
SMA 50/200
0.68x5.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-0%39.6
FUNDAMENTALS
Market Cap
$32.1B
P/E (Forward)
—
Gross Margin
71.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZTS.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZTS.MX | Zoetis Inc.(you) | $32.1B | 82 | STRONG BUY |
| UTHR | United Therapeutics Corporation | $23.0B | 88 | STRONG BUY |
| VTRS | Viatris Inc. | $19.0B | 86 | STRONG BUY |
| NBIX | Neurocrine Biosciences, Inc. | $16.9B | 94 | STRONG BUY |
| ELAN | Elanco Animal Health Incorporated | $12.3B | 62 | HOLD |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.5B | 87 | STRONG BUY |
| LNTH | Lantheus Holdings, Inc. | $7.1B | 93 | STRONG BUY |
| INDV | Indivior Pharmaceuticals, Inc. | $4.9B | 90 | STRONG BUY |
| PBH | Prestige Consumer Healthcare Inc. | $2.3B | 78 | BUY |
| LQDA | Liquidia Corporation | $7.0B | 52 | HOLD |
Peer medians: ROE -22.1% · P/E 27.4x · Gross margin 44.3%